[go: up one dir, main page]

ATE321537T1 - Pharmazeutische zubereitung enthaltend doxazosin - Google Patents

Pharmazeutische zubereitung enthaltend doxazosin

Info

Publication number
ATE321537T1
ATE321537T1 AT02291474T AT02291474T ATE321537T1 AT E321537 T1 ATE321537 T1 AT E321537T1 AT 02291474 T AT02291474 T AT 02291474T AT 02291474 T AT02291474 T AT 02291474T AT E321537 T1 ATE321537 T1 AT E321537T1
Authority
AT
Austria
Prior art keywords
doxazosine
pharmaceutical preparation
preparation containing
doxazosin
core
Prior art date
Application number
AT02291474T
Other languages
English (en)
Inventor
Pawan Seth
Original Assignee
Cimex Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cimex Pharma Ag filed Critical Cimex Pharma Ag
Application granted granted Critical
Publication of ATE321537T1 publication Critical patent/ATE321537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02291474T 2001-09-14 2002-06-13 Pharmazeutische zubereitung enthaltend doxazosin ATE321537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/953,072 US20030059467A1 (en) 2001-09-14 2001-09-14 Pharmaceutical composition comprising doxasozin

Publications (1)

Publication Number Publication Date
ATE321537T1 true ATE321537T1 (de) 2006-04-15

Family

ID=25493537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02291474T ATE321537T1 (de) 2001-09-14 2002-06-13 Pharmazeutische zubereitung enthaltend doxazosin

Country Status (8)

Country Link
US (1) US20030059467A1 (de)
EP (1) EP1293196B1 (de)
AT (1) ATE321537T1 (de)
CY (1) CY1106084T1 (de)
DE (1) DE60212734T2 (de)
DK (1) DK1293196T3 (de)
ES (1) ES2259698T3 (de)
PT (1) PT1293196E (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040162320A1 (en) * 2003-02-14 2004-08-19 Pawan Seth Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant
CN100391459C (zh) * 2003-05-26 2008-06-04 沈阳药科大学 甲磺酸多沙唑嗪缓释制剂
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2005037247A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Oral matrix formulations of doxazosin
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006129966A1 (en) * 2005-05-31 2006-12-07 Ctc Bio, Inc. Manufacturing method of controlled-release tablet containing doxazocin mesylate
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
RU2508092C2 (ru) 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
CN102058555A (zh) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 一种多沙唑嗪控释片
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
NO2736497T3 (de) 2011-07-29 2018-01-20
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
CN104224756A (zh) * 2014-09-26 2014-12-24 天津市聚星康华医药科技有限公司 一种甲磺酸多沙唑嗪口腔速溶膜及其制备方法
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
EP1293196A3 (de) 2004-01-02
US20030059467A1 (en) 2003-03-27
PT1293196E (pt) 2006-05-31
ES2259698T3 (es) 2006-10-16
EP1293196A2 (de) 2003-03-19
EP1293196B1 (de) 2006-03-29
CY1106084T1 (el) 2011-06-08
DE60212734T2 (de) 2006-11-09
DK1293196T3 (da) 2006-07-17
DE60212734D1 (de) 2006-08-03

Similar Documents

Publication Publication Date Title
ATE321537T1 (de) Pharmazeutische zubereitung enthaltend doxazosin
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
NO973922L (no) Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
HUP0401783A3 (en) 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands, their use and pharmaceutical compositions containing them
TW200505406A (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
MA26129A1 (fr) Melange insecticide contenant de la gamma-cyhalothrine
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
EE05183B1 (et) Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
HUP0402047A3 (en) 7,9-substituted tetracycline compounds, their use and pharmaceutical compositions containing them
HUP0303825A3 (en) 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them
HUP0401109A3 (en) Nociceptin analogs, their use and pharmaceutical compositions containing them
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
HUP0400967A3 (en) Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
DE60235648D1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
SE0200657D0 (sv) Novel Formulation
YU82693A (sh) Farmaceutske formulacije disulfonil metana i novi disulfonil metani
EA200400343A1 (ru) Композиция с контролируемым высвобождением кларитромицина или тинидазола
BRPI0212195B8 (pt) composições contendo pectina e ácido ascórbico
MXPA02012015A (es) Ligandos de receptores para integrinas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1293196

Country of ref document: EP

EEIH Change in the person of patent owner